PDCD1 and melanoma: ,68 Other studies in melanoma patients have shown that patients with higher levels of Faecalibacterium spp (in particular F. prausnitzii) during treatment with anti-PD-1, anti-CTLA-4, or a combination of both experienced better clinical outcomes (Figure 2; Table 1).46